Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-08-15 Management Reports
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
安杰思2023 年股权激励首次授予激励对象名单
Management Reports Classification · 90% confidence The document is a list of stock option incentive plan recipients for the year 2023, detailing the allocation of restricted stock to directors, senior management, and other key personnel. It includes specific numbers of shares granted and percentages relative to the total incentive plan. The document is a formal announcement of the stock option grant details rather than a full report or financial statement. It does not contain financial results, audit information, or regulatory certifications. It is also not a proxy solicitation or voting result announcement. Given the content focuses on the allocation of stock incentives to management and employees, it fits best under the category of Management Reports (MDA), which includes detailed explanations of business trends and management-related information such as stock incentive plans.
2023-08-15 Chinese
安杰思关于监事辞职暨补选监事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company supervisor and the subsequent election of a new supervisor. It includes details about the resignation, the legal basis for the resignation and replacement, and information about the new candidate. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to annual or interim reports. The content clearly relates to changes in company governance personnel, specifically the supervisory board. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused on personnel changes, not a report or announcement of a report publication.
2023-08-15 Chinese
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023 年半年度持续督导跟踪报告" which translates to "2023 Semi-Annual Continuous Supervision Tracking Report" issued by the sponsor (中信证券股份有限公司) for the company 杭州安杰思医学科技股份有限公司. It references the 2023 half-year period (1-6 months) and contains detailed financial data, risk factors, business updates, and compliance information. The document is comprehensive and includes actual financial figures and analysis for the half-year period, indicating it is a substantive financial report rather than a mere announcement or certification. The content aligns with an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes financial statements and management discussion. It is not an Annual Report (10-K) because it covers only half a year, nor is it a simple announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-08-15 Chinese
安杰思2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Half-Year Report Summary'. It contains financial data for the half-year period, including total assets, net profit, revenue, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report on the official website. The document length is 2954 characters, which is relatively short and appears to be a summary rather than the full report. However, it contains substantive financial data and analysis for the half-year period, including financial metrics and shareholder details. According to the definitions, an Interim / Quarterly Report (IR) is a comprehensive financial report for a period shorter than a full fiscal year and must contain actual financial statements or substantive financial data and analysis. This document fits that description as it provides key financial data and analysis for the half-year period. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2023
2023-08-15 Chinese
安杰思2023年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2023 年半年度报告" which translates to "2023 Semi-Annual Report." It covers the period from January 1, 2023 to June 30, 2023, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, cash flow, assets, and earnings per share. It also contains management discussion and analysis, company overview, business model, core technologies, and R&D progress. The document length is about 15,000 characters, which is substantial and contains actual financial statements and substantive analysis. The document explicitly states it is an unaudited half-year report and includes signatures from responsible officers. This matches the definition of an Interim / Quarterly Report (IR). It is not an announcement or a brief summary, nor is it a full annual report (10-K). Therefore, the correct classification is IR with high confidence. H1 2023
2023-08-15 Chinese
安杰思关于设立全资子公司的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Hangzhou Anjiese Medical Technology Co., Ltd. about the establishment of a wholly-owned subsidiary. It details the investment amount, company information, and risk analysis related to the new subsidiary. There is no financial data, earnings information, or detailed report content. The document is a formal announcement of a capital investment and company structure change, not a financial report or management discussion. It fits the category of Capital/Financing Update (CAP) as it relates to company fundraising or capital structure changes through the establishment of a new subsidiary.
2023-08-15 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.